The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic
RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in …

The past decade has brought significant advances in our understanding of the molecular
mechanisms of thyroid carcinogenesis. Among thyroid carcinomas, the most successful …

RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have
revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer …

Aim While most patients with RET-altered cancer responded to the RET protein tyrosine
kinase inhibitors (TKIs) pralsetinib (BLU667) and selpercatinib (LOXO292), few achieved a …

Abstract Selpercatinib (LOXO292) and pralsetinib (BLU667) are RET protein tyrosine kinase
inhibitors (TKIs) recently approved for treating RET-altered cancers. However, RET …

RET gene plays significant roles in the nervous system and many other tissues. Rearranged
during transfection (RET) mutation is related to cell proliferation, invasion, and migration …

While activating RET fusions are identified in various cancers, lung cancer represents the
most common RET fusion-positive tumor. The clinical drug development of RET inhibitors in …

Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors,
which seriously affects human health. Although surgical resection offers a potentially …

Background: Rearranged during transfection (RET) is a receptor tyrosine kinase and a bona
fide oncogene that drives various cancers. Oncogenic RET induces abnormal activation of …

Simple Summary Rearranged during transfection (RET) is a transmembrane receptor
tyrosine kinase that shows targetable mutations and gene fusions in a few types of cancers …